LCI133
LCI133 is afirst-in-class, nanomolar-potent, selective multikinase inhibitor targeting CDK4/6/9 and AURKA/B (IC50 = 4.7/10.2/4.1 nM and 2.8/10.6 nM) . LCI133 induces S/G2 cell-cycle arrest and robust apoptosis in MYCN-amplified neuroblastoma BE (2) -C cells. LCI133 demonstrates significant antitumor efficacy in a BE (2) -C neuroblastoma xenograft model[1].
Product Specifications
CAS Number
[3065284-87-6]
UNSPSC
12352005
Target
Aurora Kinase; CDK
Related Pathways
Cell Cycle/DNA Damage; Epigenetics
Field of Research
Cancer
Smiles
CN(C(C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=CC=C(C=C4)C5=CC6=C(C(C=C(O6)N7CCOCC7)=O)C=C5)=O)C
Molecular Formula
C33H34N6O4
Molecular Weight
578.66
References & Citations
[1]Maddeboina K, et al. Discovery of a "First-in-Class" Selective Multikinase (CDK4/6/9-AURKA/B) Inhibitor, LCI133, for Neuroblastoma.J Med Chem. 2025;68 (22) :24024-24046. doi:10.1021/acs.jmedchem.5c01688
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Aurora A; Aurora B; CDK4; CDK6; CDK9
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
